Insulet has begun distributing an updated version of its Omnipod 5 automated insulin delivery (AID) system across the US, following 510(k) clearance from the US Food and Drug Administration (FDA) in December 2025.
The latest software changes are accessible to both new and existing users nationwide, accompanied by Omnipod 5’s new capacity to work with Abbott’s FreeStyle Libre 3 Plus sensor. This update allows additional flexibility for individuals managing diabetes.
Insulet has incorporated a new algorithm into Omnipod 5, marking the system’s most significant change since its introduction in 2022.
The update offers healthcare professionals and patients six target glucose options ranging from 100mg/dL to 150mg/dL, including a new 100mg/dL target glucose choice.
The algorithm also seeks to minimise breaks in Automated Mode operation, even if users experience prolonged elevated glucose readings.
Insulet has begun shipping Omnipod 5 pods with the new algorithm to US retailers ahead of a broader software update.
Users will receive the new features via an over-the-air update to either their Omnipod 5 Controller or compatible mobile application, provided they have access to the updated pods.
Beyond the algorithm advancement, Omnipod 5’s compatibility now extends to Abbott’s Libre 3 Plus sensor for users in the US.
This integration allows caregivers to monitor patient information through Abbott’s LibreLinkup app. Insulet also intends to broaden this compatibility to other countries later this year.
Insulet COO and executive vice-president Eric Benjamin said: “Delivering innovations that make diabetes management easier is at the heart of everything we do. These enhancements deliver what users tell us matters most: smarter automation, more personalisation, better control, and expanded choice.
“By offering a lower target glucose option and expanding sensor compatibility, we’re helping people spend less time making decisions about diabetes and more time feeling confident, supported, and in control.”
Last month, Insulet commenced patient enrolment in its pivotal EVOLVE study, evaluating a fully closed-loop AID system for adults with type 2 diabetes.
